Literature DB >> 7629593

Species-dependent binding of copper(II) bis(thiosemicarbazone) radiopharmaceuticals to serum albumin.

C J Mathias1, S R Bergmann, M A Green.   

Abstract

UNLABELLED: Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)-copper(II) (Cu-PTSM) is a generator-based PET radiopharmaceutical under investigation for use in evaluation of tissue perfusion. Despite promising results from animals, problems have been encountered in the use of 62Cu-PTSM to quantitate myocardial perfusion in humans at high flow rates, possibly due to species-dependent interactions of the tracer with serum albumin.
METHODS: Ultrafiltration and plasma/erythrocyte partitioning studies were performed to assess the protein binding of 67Cu-labeled Cu-PTSM and six related copper(II) bis(thiosemicarbazone) complexes.
RESULTS: These studies reveal significant interspecies variability in the strength of Cu-PTSM binding to serum albumin, with 67Cu-PTSM binding much more strongly to human albumin than to dog albumin. Most of the related Cu(II)-bis(thiosemicarbazone) complexes examined exhibit interspecies variability of albumin binding similar to that observed with Cu-PTSM. Two such complexes, Cu-ETS and Cu-n-PrTS, however, were identified that exhibit no preferential association with human serum albumin.
CONCLUSION: Copper-62-PTSM exhibits substantial interspecies variability in the strength of its binding to serum albumin, which appears to explain the problems encountered in using animal data to predict 62Cu-PTSM behavior in humans. The 62Cu-ETS and 62Cu-n-PrTS complexes may be viable alternatives to 62Cu-PTSM for PET studies to evaluate quantitatively myocardial blood flow in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7629593

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Journey to find the ideal PET flow tracer for clinical use: are we there yet?

Authors:  David K Glover; Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2007 Nov-Dec       Impact factor: 5.952

Review 2.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.

Authors:  Shuang Liu
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

3.  Copper-62-pyruvaldehyde bis(N-methyl-thiosemicarbazone) PET imaging in the detection of coronary artery disease in humans.

Authors:  T R Wallhaus; J Lacy; R Stewart; J Bianco; M A Green; N Nayak; C K Stone
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

4.  Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography.

Authors:  Nona Adonai; Nora Adonai; Khoi N Nguyen; Joseph Walsh; M Iyer; Tatsushi Toyokuni; Michael E Phelps; Timothy McCarthy; Deborah W McCarthy; Sanjiv Sam Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

5.  Species dependence of [64Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins.

Authors:  Nathan E Basken; Carla J Mathias; Alexander E Lipka; Mark A Green
Journal:  Nucl Med Biol       Date:  2008-01-30       Impact factor: 2.408

6.  Changes in regional brain perfusion during functional brain activation: comparison of [(64)Cu]-PTSM with [(14)C]-Iodoantipyrine.

Authors:  D P Holschneider; J Yang; T R Sadler; N B Galifianakis; M H Bozorgzadeh; J R Bading; P S Conti; J-M I Maarek
Journal:  Brain Res       Date:  2008-07-19       Impact factor: 3.252

Review 7.  Mapping brain function in freely moving subjects.

Authors:  Daniel P Holschneider; Jean-Michel I Maarek
Journal:  Neurosci Biobehav Rev       Date:  2004-09       Impact factor: 8.989

8.  Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals.

Authors:  Nathan E Basken; Carla J Mathias; Mark A Green
Journal:  J Pharm Sci       Date:  2009-06       Impact factor: 3.534

9.  Cu(II) bis(thiosemicarbazone) radiopharmaceutical binding to serum albumin: further definition of species dependence and associated substituent effects.

Authors:  Nathan E Basken; Mark A Green
Journal:  Nucl Med Biol       Date:  2009-05-08       Impact factor: 2.408

Review 10.  Development of copper based drugs, radiopharmaceuticals and medical materials.

Authors:  Paweł Szymański; Tomasz Frączek; Magdalena Markowicz; Elżbieta Mikiciuk-Olasik
Journal:  Biometals       Date:  2012-08-23       Impact factor: 2.949

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.